- Home
- AKTX vs EQ Comparison
AKTX vs EQ Comparison
Compare AKTX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- EQ
- Stock Information
- Founded
- AKTX N/A
- EQ 2017
- Country
- AKTX United States
- EQ United States
- Employees
- AKTX 12
- EQ N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- EQ Health Care
- Exchange
- AKTX Nasdaq
- EQ Nasdaq
- Market Cap
- AKTX 25.7M
- EQ 31.1M
- IPO Year
- AKTX N/A
- EQ 2018
- Fundamental
- Price
- AKTX $0.97
- EQ $0.88
- Analyst Decision
- AKTX
- EQ Buy
- Analyst Count
- AKTX 0
- EQ 2
- Target Price
- AKTX N/A
- EQ $5.00
- AVG Volume (30 Days)
- AKTX 30.9K
- EQ 2.2M
- Earning Date
- AKTX 03-04-2025
- EQ 03-24-2025
- Dividend Yield
- AKTX N/A
- EQ N/A
- EPS Growth
- AKTX N/A
- EQ N/A
- EPS
- AKTX N/A
- EQ N/A
- Revenue
- AKTX N/A
- EQ $45,914,000.00
- Revenue This Year
- AKTX N/A
- EQ $4.77
- Revenue Next Year
- AKTX N/A
- EQ N/A
- P/E Ratio
- AKTX N/A
- EQ N/A
- Revenue Growth
- AKTX N/A
- EQ 7.70
- 52 Week Low
- AKTX $0.90
- EQ $0.49
- 52 Week High
- AKTX $4.40
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- AKTX 39.06
- EQ 58.42
- Support Level
- AKTX $1.00
- EQ $0.85
- Resistance Level
- AKTX $1.08
- EQ $0.98
- Average True Range (ATR)
- AKTX 0.12
- EQ 0.10
- MACD
- AKTX -0.02
- EQ 0.01
- Stochastic Oscillator
- AKTX 5.00
- EQ 62.50
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.